The spectrum of cutaneous T-cell lymphomas: New insights into biology and therapy

Christiane Querfeld, Steven T. Rosen, Joan Guitart, Timothy M. Kuzel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


Purpose of review: Cutaneous T-cell lymphomas represent clinically and biologically a heterogeneous group of non-Hodgkin lymphomas according to the new revised European Organization for Research and Treatment of Cancer and World Health Organization consensus classification for cutaneous lymphomas. Recent progress in immune and molecular biology and novel therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review outlines the most recent advances. Recent findings: New immunologic and molecular findings may influence tumor phenotype and growth and provide a biologic basis for novel treatment approaches. Several reports have focused on new prognostic markers. Among the novel therapies for cutaneous T-cell lymphoma, interleukin-2 fusion toxins, monoclonal antibodies, histone deacetylase inhibitors, and immunomodulatory cytosine-phosphorothiolated guanine oligomers have shown promising results and are under further investigation. Summary: This review provides an update of recent findings of immunologic, molecular, and cytogenetic features and treatment approaches for patients with cutaneous T-cell lymphoma with special emphasis on mycosis fungoides and Sézary syndrome.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalCurrent Opinion in Hematology
Issue number4
StatePublished - Jul 1 2005


  • Biologic properties
  • Cutaneous T-cell lymphoma
  • Molecular and cytogenetic abnormalities
  • Prognostic factors
  • Treatment

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The spectrum of cutaneous T-cell lymphomas: New insights into biology and therapy'. Together they form a unique fingerprint.

Cite this